Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pevion Biotech has granted Australia-based CSL a right of first refusal to an exclusive license for the commercialization of Pevion’s PEV7 therapeutic vaccine in Australia and New Zealand.
Subscribe to our email newsletter
PEV7 is a therapeutic vaccine based on a protein antigen, Sap2, a key virulence factor of vulvovaginal candidiasis, presented on the surface of virosomes.
The companies have also signed a long-term supply agreement under which CSL will supply Pevion with components for its virosomal vaccines.
Pevion Biotech said the PEV7 already obtained preliminary clinical results showing that the therapeutic vaccine is safe and immunogenic in healthy volunteers.
Pevion Biotech also said the ongoing PEV7 Phase I study is designed to demonstrate the safety and immunogenicity of the therapeutic vaccine candidate in healthy volunteers.